Jefferies analyst Akash Tewari notes that new Medicare Part B & D draft guidance has been released and that Merck (MRK) and Bristol Myers (BMY) are trading down due to updated language on single ...

With pricing reforms and PBM overhauls looming, pharma investors need to differentiate between companies that can absorb ...